Simone Anna Mader, PhD

Instructor, The Feinstein Institute for Medical Research

Phone: (516) 562-2908
Email: smader@northwell.edu

About the Investigator

Dr. Simone Mader completed her PhD at the Medical University of Innsbruck, Austria in the Department of Neurology. For her PhD studies she has been working on autoantibodies in Multiple sclerosis and Neuromyelitis optica (NMO). Her work focused on anti-aquaporin-4 autoantibodies and their relevance for disease pathogenesis in NMO spectrum disorders.

Dr. Simone Mader is currently working as a postdoctoral fellow in the lab of Dr. Betty Diamond studying anti-brain antibodies in lupus and NMO. She is an S.L.E. Foundation fellow.

Research Focus

Since joining Dr Betty Diamond’s group at The Feinstein Institute for Medical Research, Simone Mader’s research has focused on brain reactive autoanitbodies in neuropsychiatric lupus patients and neuromyelitis optica.

Education

Leopold-Franzens University, Innsbruck, Austria
Degree: BS
2005
Field of Study: Biology

Leopold-Franzens University, Innsbruck, Austria
Degree: Mag.Biol
2006
Field of Study: Master program in Molecular Biology

Innsbruck Medical University, Austria
Degree: PhD
2011
Field of Study: Neuroimmunology

Awards & Honors

2017 AWSM Post Doctoral Fellows Award, AWSM received by Advancing Women in Science and Medicine, The Feinstein Institute for Medical Research
2017 Autism Society Award for best manuscript (Brimberg & Mader et al.,)
2017 Speaker Recognition Award, 2017 Annual Feinstein Institute for Medical Research Retreat, Cold Spring Harbor
2016 Excellence in Research award (Betty Diamond, Lior Brimberg, Simone Mader and their team), The Feinstein Institute, New York
2016 Deirdre Costa Major Post Doctoral Educational Award from Advancing Women in Science and Medicine (AWSM), The Feinstein Institute, NY
2016 C/STEP Research Mentor Award, Science and Technology Entry Program (STEP)/Science and Technology Entry Program, Farmingdale State College
2015 FOCIS Travel Award: received from the Federation of Clinical Immunology Societies/San Diego
2015 FOCIS poster award: received from the Federation of Clinical Immunology Societies/San Diego
2015 4th European Congress of Immunology, travel grant, Vienna
2013 Basic Science Fellowship Grant, S.L.E. Foundation, Inc., 2013-2015
2013 FOCIS Travel Award, Boston
2012 Ursula & Fritz Melchers Award for the PhD thesis and PhD Award of the Austrian Society of Allergology and Immunology (ÖGAI)
2011 Poster Prize at the XI Neuroscience Wintermeeting, Kitzbühel, Austria
2010 Poster Prize at the 8th Annual Meeting of the Austrian Neurological Society (ÖGN), Linz, Austria
2009 Poster Prize at the Neuroscience Day, Innsbruck, Austria

Publications
  1. Hennes E, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl H, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt S, Mader S, et al., “Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.” 2017, Neurology, in press
  2. Brimberg L*, Mader S*, Jeganathan V, Berlin R, Gregersen P, Huerta P, Volpe B, Diamond B, “Caspr2-reactive antibody cloned from a mother of an ASD child mediates ASD-like phenotype in mice.” Molecular Psychiatry 2016. * authors contributed equally
  3. Honig G, Mader S, Chen H, Porat A, Ochani M, Wang P, Volpe BT, Diamond B. “Blood-Brain Barrier Deterioration and Hippocampal Gene Expression in Polymicrobial Sepsis: An Evaluation of Endothelial MyD88 and the Vagus Nerve.” PLoS One. 2016;11(1):e0144215.
  4. Zeka B, Hastermann M, Hochmeister S, Koegel N, Kaufmann N, Schanda K, Mader S, et al., “Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.” Acta Neuropathol. 2015;130(6):783-98.
  5. Chang E, Volpe B, Mackay M, Aranow C, Watson P, Kowal C, Storbeck J, Mattis P, Berlin R, Chen H, Mader S et al., “Selective impairment of spatial cognition caused by autoantibodies to the N-methyl-D-aspartate receptor.” EbioMedicine, 2015;2(7):755-64
  6. Brimberg L, Mader S, Fujieda Y, Kowal C, et al, “Antibodies as mediators of brain pathology.” Trends in Immunol, 2015; 36(11):709-24.
  7. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al., “Clinical and neuroradiological differences of pediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.” J Neurol Neurosurg Psychiatry. 2015;86(3):265-72.
  8. Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, Machado-Santos J, Mader S et al., “T cell-activation in neuromyelitis optica lesions plays a role in their formation.” Acta Neuropathol Commun. 2013;1(1):85.
  9. Diamond B, Honig G, Mader S, Brimberg L, and T. Volpe B. “Brain-Reactive Antibodies and Disease.”Annual Review of Immunology Vol. 31, 2013 Mar 21;31:345-85.
  10. Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl M, Fujihara K, Lassmann H, Bradl M; “Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats.” Acta Neuropathologica Communications. 2013.
  11. Rostásy K, Mader S, Hennes E, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M. “Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.” Mult Scler. 2012 Jun;69(6):752-6.
  12. Gredler V*, Mader S*, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A; “Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.” Journal Neurol Science. 2013 May, 15;328(1-2):77-82. *These authors contributed equally to the manuscript.
  13. Rostasy K, Mader S, Di Pauli F, Huppke P, Gärtner J, Marquart F, Karenfurt M, Tibussek D, Blaschek A, Kornek B, Leitz S, Berger T, Reindl M. “Anti-MOG-IgG antibodies in pediatric patients with optic neuritis.” Archives of Neurology. 2012;69(6):752-756.
  14. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch M K, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M; “Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.” Journal of Neuroinflammation. 2011 Dec | 8:184.
  15. Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Reindl M, Kleiter I, Ruprecht K, Kristoferitsch W, Melms A, Wandinger K, Wildemann B. “Frequency and syndrome speci”city of antibodies to aquaporin-4 in neurological patients with rheumatic diseases.” Multiple Sclerosis Journal. 2011 Sep | 17(9):1067-73.
  16. Pohl M, Fischer M, Mader S, Schanda K, Kitic M, Sharma R, MisuT, Fujihara K, Reindl M, Lassmann H & Bradl M. “Pathogenic T cell responses against aquaporin 4.” Acta Neuropathologica. 2011 Jul | 122(1):21-34.
  17. Dujmovic I*, Mader S*, Schanda K, Deisenhammer F, Stojsavljevic N, Kostic V, Berger T, Drulovic J, Reindl M. “Temporal dynamics of cerebrospinal fluid anti aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.” Journal of Neuroimmunology. 2011 May | 234(1-2):124-30. * These authors contributed equally to the manuscript.
  18. Di Pauli F*, Mader S*, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T. “Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.” Clinical Immunology. 2011 Mar | 138(3):247-54. *These authors contributed equally to the manuscript.
  19. Mader S, Lutterotti A, Di Pauli F, Kuenz B, Schanda K, Aboul-Enein F, Khalil M, Storch MK, Jarius S, Kristoferitsch W, Berger T, Reindl M. “Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.” PLoS One. 2010 May | 5(5):e10455.
  20. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H. “Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.” Annals of Neurology. 2009 Nov | 66(5):630-43.

View more at PubMed